SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

The company, founded by 25-year-old Kian Sadeghi, announced a $14 million Series A, bringing its total funding to about $32 million.

Health systems across the country are making it easier for primary care clinicians to order genetic tests for patients who ...

Matthew Moll, MD, MPH, and Michael H. Cho, MD, MPH, from the Department of Medicine at Brigham and Women's Hospital are ...

Rutgers Health researchers have discovered that brain immune cells from people with a high genetic risk for alcohol use ...

Seattle doctors developed a blood test that determines the parental origin of the RB1 mutation in retinoblastoma.

This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

Some psychiatric disorders have many overlapping symptoms, which can make it very challenging to diagnose a specific disease. | Clinical And Molecular Dx ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a ...

The NHS has launched a new genetic blood test to improve the safety of kidney donations from people of Black African and ...